Health Care·Biotechnology·$24.9B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.79 | N/A | -9.30% |
management commentary, guidance changes, and full analysis available with Pro.
| -9.30% |
Tone: Defensive
Management acknowledged the difficulties faced in the quarter. They emphasized a focus on navigating current market conditions.
Management expressed concerns about ongoing market challenges.
They highlighted the need for strategic adjustments moving forward.
The earnings report indicates that United Therapeutics fell short of expectations on EPS, which contributed to a 3.41% decline in stock price. Investors may be concerned about the company's ability to navigate market challenges effectively. Without updated guidance, uncertainty remains about future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
CHARLES RIV LABORATO
Feb 13, 2012